SCHEMBL5364633

SCHEMBL5364633

O=C1Nc2ccc(CCCl)cc2C1=Cc1cc([N+](=O)[O-])cc(CCl)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 1/20 0.45
GSK3B P49841 8/20 0.44
RET P07949 3/20 0.43
PDGFRB P09619 2/20 0.41
JAK3 P52333 1/20 0.41
DHFR P00374 1/20 0.41
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
RPS6KA5 O75582 1/20 0.38
ABL1 P00519 1/20 0.38
LCK P06239 1/20 0.38
LYN P07948 1/20 0.38
MET P08581 1/20 0.38
KIT P10721 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
SRC P12931 1/20 0.38
PDGFRA P16234 1/20 0.38
PRKCA P17252 1/20 0.38
FGFR3 P22607 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369503 0.86 RAF1 (0.49) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5367333 0.85 NOX4 (0.58) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL7136333 0.79 MAPT (0.61) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL7135240 0.79 KDR (0.44) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5361064 0.77 RAF1 (0.46) PDGFRBRPS6KA3PTPN1
SCHEMBL5368525 0.76 GSK3B (0.38) NOX4GSK3BRETPDGFRBJAK3
SCHEMBL5366371 0.76 RAF1 (0.50) PIM1MAPT
SCHEMBL5366154 0.76 NOX4 (0.44) NOX4GSK3BRETCCNE1CDK2
SCHEMBL5369296 0.75 NOX4 (0.58) NOX4GSK3BAPPMAPTSNCA
SCHEMBL5366866 0.75 NOX4 (0.58) NOX4GSK3BAPPMAPTSNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NOX4 3452/4885GSK3B 315/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.